Can a transplanted living donor kidney function equivalently to its native partner?

American Journal of Transplantation

Volumn 2, Issue 3, 2002, Pages 252-259

  Velosa, Jorge A ^a   Griffin, Matthew D ^a   Larson, Timothy S ^a   Gloor, James M ^a   Schwab, Thomas R ^a   Sterioff, Sylvester ^a   Bergstralh, Erik J ^a   Stegall, Mark D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cyclosporine; Functional adaptation; Glomerular filtration rate; Haploidentical; Kidney; Renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY COMPENSATORY HYPERTROPHY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LINEAR REGRESSION ANALYSIS; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY;

CYCLOSPORINE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HAPLOTYPES; HUMANS; HYPERTROPHY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVING DONORS; NEPHRECTOMY; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036524036     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2002.20310.x     Document Type: Article

References (40)

1. Welsh CA, Wellen I, Taylor HC, Rosenthal A. Changes in renal function accompanying the hypertrophy of the remaining kidney after unilateral nephrectomy. J Clin Invest 1944; 23: 750-763.
2. Fine L. The biology of renal hypertrophy. Kidney Int 1986; 29: 619-634.
3. Wolf G. Molecular mechanisms of renal hypertrophy: role of p27Kip1. Kidney Int 1999; 56: 1262-1265.
4. Argiles A, Mourad G, Basset N et al. Acute adaptive changes to unilateral nephrectomy in humans. Kidney Int 1987; 32: 714-720.
5. Velosa JA, Offord KP, Schroeder DR. Effect of age, sex, and glomerular filtration rate on renal function outcome of living kidney donors. Transplantation 1995; 60: 1618-1621. Error! Bookmark not defined.
6. Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. Lancet 1992; 340: 807-810.
7. Eberhard OK, Kliem V, Offner G et al. Assessment of long-term risks for living related kidney donors by 24-h blood pressure monitoring and testing for microalbuminuria. Clin Transplant 1997; 11: 415-419.
8. Jones J, Payne WD, Matas AJ. The living donor - risks, benefits, and related concerns. Transplant Rev 1993; 7: 115-128.
9. Gridelli B, Remuzzi G. Strategies for making more organs available for transplantation. New Engl J Med 2000; 343: 402-410.
10. Kasiske BL. Clinical correlates to chronic allograft nephropathy. Kidney Int 1997: 63: S71-S7.
11. Tilney NL, Guttmann RD. Effects of initial ischemia/reperfusion injury on the transplanted kidney. Transplantation 1997; 64: 945-947.
12. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
13. Ponticelli C, Tarantino A, Vegeto A. Renal transplantation, past, present and future. J. Nephrol 1999; 12(Suppl. 2): S105-110.
14. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036-1042.
15. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999; 56: 783-793.
16. Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 2000; 20: 126-147.
17. Wilhelm MJ, Kusaka M, Pratschke J, Tilney NL. Chronic rejection: increasing evidence for the importance of allogen-dependent factors. Transplant Proc 1998; 30: 2402-2406.
18. [125]iothalamate. Mayo Clin Proc 1975; 50: 664.
19. Kries H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-1260.
20. Hricik DE. Improved renal function with cyclosporine elimination in sirolimus-treated renal transplant recipients: one year results from a phase II trial. Am J Transplant 2001, 1 (Suppl. 1): 149.
21. Gjertson DW, Cecka JM. Living unrelated donor kidney transplantation. Kidney Int 2000; 58: 491-499.
22. Terasaki PI, Cecka M, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333: 333-336.
23. Bricker NS, Guild WR, Reardan JB, Merrill JP. Studies on the functional capacity of a denervated homotransplanted kidney in an identical twin with parallel observations in the donor. J Clin Invest 1956; 35: 1364-1380.
24. Ogden DA. Donor and recipient function 2-4 years after renal homotransplantation. Ann Int Med 1967; 67: 998-1006.
25. Flanigan WJ, Burns RO, Tackas FJ et al. Serial studies of glomerular filtration rate and renal plasma flow in kidney transplant donors, identical twins, and allograft recipients. Am J Surg 1968; 116: 788.
26. Donadio JV, Farmer CD, Hunt JC, Tauxe WN, Hallenbeck GA, Shorter RG. Renal function in donors and recipients of renal allotransplantation. Ann Int Med 1967; 66: 750-763.
27. Kamper A, Holstein-Ratlou N, Strandgaard S et al. Glomerular filtration rate and segmental tubular function in the early phase after transplantation/uninephrectomy in recipients and their living donors. Clin Sci (Colch) 1994; 87: 519.
28. Ter Wee PM, Tegzess AM, Donker AJM. Pair-tested renal reserve filtration capacity in kidney recipients and their donors. J Am Soc Nephrol 1994; 4: 1798-1808.
29. Provoost AP, de Keijzer MH, Kort WJ, Wolff ED, Molenaar JC. The glomerular filtration rate of isogeneically transplanted rat kidneys. Kidney Int 1982; 21: 459-465.
30. Churchill M, Churchill PC, Schwartz M, Bidani A, McDonald F. Reversible compensatory hypertrophy in transplanted Brown Norway rat kidneys. Kidney Int 1991; 40: 13-20.
31. Schurek HJ, Neumann KH, Jesinghaus WP, Aeikens B, Wonigeit K. Influence of cyclosporine A on adaptive hypertrophy after unilateral nephrectomy in the rat. Clin Nephrol 1986; 25: S144-147.
32. Churchill M, Kline R, Schwartz M, Bidani A, Churchill P. Kidney transplants in cyclosporine-treated Sprague-Dawley rats. Transplantation 1990; 49: 8-13.
33. Ishikawa I, Shikura N, Shinoda A, Fukada Y, Tsugawa R, Suzuki K. Compensatory hypertrophy of renal grafts with triple drug therapy. Jpn J Nephrol 1990; 32: 929-932.
34. Lewis R, Rodbielski J, Sprayberry S et al. Stability of renal allograft glomerular filtration rate associated with long-term use of cyclosporine A. Transplantation 1994; 55: 1014.
35. et al. Sobh MA, El-Sherif AK, Gaber O, Ghoneim MA. Radioisotopic evaluation of renal function in cyclosporine-treated pediatric and adult renal transplant recipients and their living donors: a study of 152 donor-recipient pairs. Transplantation 1994; 58: 1171-1175.
36. Carins HS, Raval U, Neild GH. Failure of cyclosporine-treated renal allograft recipients to increase glomerular filtration rate following an amino acid infusion. Transplantation 1988; 46: 79-82.
37. Hakim RM, Goldszer RC, Brenner BM. Hypertension and proteinuria: long-term sequelae of uninephrectomy in humans. Kidney Int 1984; 35: 930-936.
38. Taal MW, Tilney NL, Brenner BM, Mackenzie HS. Renal mass: an important determinant of late allograft outcome. Transplant Rev 1998; 12: 74-84.
39. Terasaki PI, Koyama H, Cecka JM, Gjertson DW. The hyperfiltration hypothesis in human renal transplantation. Transplantation 1994; 57: 1450-1454.
40. Anderson CF, Velosa JA, Frohnert PP et al. The risks of unilateral nephrectomy: status of kidney donors 10-20 years postoperatively. Mayo Clin Proc 1985; 60: 367-374.